Bio-Gene Technology Limited (BGT.AX)

AUD 0.04

(0.0%)

Market Cap (In AUD)

7.65 Million

Revenue (In AUD)

18.32 Thousand

Net Income (In AUD)

-2.4 Million

Avg. Volume

87.55 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.036-0.085
PE
-
EPS
-
Beta Value
0.705
ISIN
AU000000BGT8
CUSIP
Q1506Q101
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Timothy Owen Grogan B.Sc., LLB
Employee Count
-
Website
https://www.bio-gene.com.au
Ipo Date
2017-11-28
Details
Bio-Gene Technology Limited, an agtech development company, engages in developing and commercializing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has research collaborations with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.